Woodford Investment Management

Broker Stifel has recommended investors sell Neil Woodford's Patient Capital trust due to its share price trading at a high premium to NAV.

The fund groups with the best Twitter strategies

The Patient Capital investment trust is to enter the FTSE 250 later this month, two months on from its record fundraising.

Fund managers give their views on the key issues impacting global asset classes and outline how they are positioning portfolios.

New guard make their mark

Jeremy Beckwith, director of manager research at Morningstar UK, analyses the key lessons that can be learned from the launch of Neil Woodford's new vehicle last month

The Battle Against Cancer investment trust (BACIT) has backed Woodford's Patient Capital trust at launch.

A chink in the armour?

Neil Woodford's record-breaking Patient Capital investment trust moved to a premium shortly after launching on the London Stock Exchange.

Woodford IM's Patient Capital trust has raised a record £800m during its offer period, and the company will be intent on avoiding the fate suffered by many of its chart-topping predecessors.